Harwin Peter Evan's Form 4 filing
Korsana Biosciences, Inc. (KRSA) · filed Sep 10, 2026
- Accession no.
- 0001193125-26-388142
- Filed
- Sep 10, 2026, 5:44 PM ET
- Trade date
- Sep 9, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 derivative transaction. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harwin Peter EvanCIK 0001663607 | Director, 10% Owner |
| Fairmount Healthcare Fund II L.P.CIK 0001769651 | Director, 10% Owner |
| Fairmount Funds Management LLCCIK 0001802528 | Director, 10% Owner |
| Kiselak TomasCIK 0001830177 | Director, 10% Owner |
| Fairmount Healthcare Co-Invest VI L.P.CIK 0002124208 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Common Stock | AGrant or awardAcquired | +48,445 | $0.00 | $0 | 48,445 | Indirect | Duplicate filing |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.